Compare CLAR & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLAR | AGEN |
|---|---|---|
| Founded | 1957 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.2M | 126.2M |
| IPO Year | 1998 | 1999 |
| Metric | CLAR | AGEN |
|---|---|---|
| Price | $3.05 | $3.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $4.85 | ★ $14.50 |
| AVG Volume (30 Days) | 264.9K | ★ 372.3K |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | ★ 11.68 | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | $228,000.00 | ★ $42,877,086.00 |
| Revenue This Year | $7.10 | $5.19 |
| Revenue Next Year | $7.09 | $68.25 |
| P/E Ratio | ★ N/A | $8.04 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $2.91 | $1.38 |
| 52 Week High | $4.17 | $7.34 |
| Indicator | CLAR | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 37.69 | 56.73 |
| Support Level | N/A | $2.90 |
| Resistance Level | $3.80 | $4.72 |
| Average True Range (ATR) | 0.14 | 0.18 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 37.33 | 75.01 |
Clarus Corp is a designer, developer, manufacturer, and distributor of outdoor equipment and lifestyle products focused on the climb, ski, mountain, sport, and skincare markets. The company operates through the Outdoor segment, which includes Black Diamond Equipment and PIEPS, is a world-wide leader in designing, manufacturing, and marketing outdoor engineered equipment and apparel for climbing, mountaineering, trail running, backpacking, skiing, and a wide range of other year-round outdoor recreation activities. The Adventure segment, which includes Rhino-Rack, MAXTRAX and TRED, is a manufacturer of engineered automotive roof racks, trays, mounting systems, luggage boxes, carriers, recovery boards and accessories in Australia and New Zealand and United States.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).